After meeting the initial requirements of the Food and Drug Administration, Abbott Nutrition resumed production at its Sturgis plant in Michigan on Saturday.
EleCare, as well as other metabolic and specialty formulas, was produced by the company. EleCare products will be available around June 20, according to company estimates.
A spokesperson for Abbott said that they are also working hard to complete the steps required to restart Similac production and other formulas. “We are aware of the urgent need for formula and our top priority, however, is to get safe, high-quality formula into the hands families all across America.
After agreeing to a consent order with the FDA, Abbott was permitted to resume production. The FDA stipulated that Sturgis must have an independent expert to oversee operations and ensure compliance with the law.
The court must approve the decree. It also contains measures to test products and stop production in case they are contaminated.
The Abbott spokesperson stated that production will be ramped up as fast as possible while still meeting all requirements. “We are committed to safety, quality, and will do all we can to earn the trust that parents, caregivers, and health care providers have placed on us for 130+ years.”
